Westside Investment Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Westside Investment Management’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12	Closed	-$14	–	1388
2025 Q2	$14	Hold	12	–	–	﹤0.01%	1277
2025 Q1	$16	Hold	12	–	–	﹤0.01%	973
2024 Q4	$28	Sell	12 -1	-8%	-$2	﹤0.01%	978
2024 Q3	$46	Hold	13	–	–	﹤0.01%	983
2024 Q2	$68	Hold	13	–	–	﹤0.01%	975
2024 Q1	$112	Hold	13	–	–	﹤0.01%	886
2023 Q4	$54	Hold	13	–	–	﹤0.01%	860
2023 Q3	$40	Hold	13	–	–	﹤0.01%	835
2023 Q2	$412	Hold	13	–	–	﹤0.01%	817
2023 Q1	$660	Hold	13	–	–	﹤0.01%	807
2022 Q4	$0	Hold	13	–	–	﹤0.01%	801
2022 Q3	$0	Hold	13	–	–	﹤0.01%	802
2022 Q2	$0	Hold	13	–	–	﹤0.01%	797
2022 Q1	$0	Hold	13	–	–	﹤0.01%	775
2021 Q4	$0	Hold	13	–	–	﹤0.01%	774
2021 Q3	$0	Hold	13	–	–	﹤0.01%	746
2021 Q2	$0	Hold	13	–	–	﹤0.01%	736
2021 Q1	$0	Hold	13	–	–	﹤0.01%	716
2020 Q4	$1	Hold	13	–	–	﹤0.01%	621
2020 Q3	$3	Hold	13	–	–	﹤0.01%	585
2020 Q2	$2	Buy	+13	New	+$1.4K	﹤0.01%	594

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Westside Investment Management's BCLI Position: Q3 2025 in Review

Westside Investment Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 12 shares — an estimated $14 sold.

Westside Investment Management first reported a position in BCLI in Q2 2020 and held it in 21 quarters. The position peaked at $660 in Q1 2023. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Westside Investment Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Westside Investment Management sold 12 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $14.
Westside Investment Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 21 quarters.
Westside Investment Management's BRAINSTORM CELL THERAPUTC position peaked at $660 in Q1 2023.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Westside Investment Management's 13F filing for Q3 2025, filed 4 Nov 2025.